

The Schechter and Berger nomenclature




FIG. 1

0
40
80
120
160
200
240
280
320
360
400
440
480
520
560
600
640
680
720
760
800
840
880
920
960





FIG. 2

7 9 5 7 6 0 7 6 9 5 5 6 5 0

β -I Tryptase P1-Lys Library



β -I Tryptase P1-Arg Library






FIG. 3A

FIG. 3B


Human β -II Tryptase P1-Lys Library



P2




P3




P4


Human β -II Tryptase P1-Arg Library



P2



P3



P4

FIG. 4A

FIG. 4B

Ac-PRNK-ACC as an Optimized Tryptase Substrate
(Tryptase v. Factor Xa v. Human thrombin)




FIG. 5

Fluorometric Tryptase Activity Assay Using Ac-PRNK-ACC in Spiked Assay Buffer




FIG. 6




FIG. 7

Use of Ac-PRNK-ACC as a Fluorometric Tryptase Substrate




FIG. 8

Exogenously Added Protease Inhibitors:
Effects on Ac-PRNK-ACC based Tryptase Activity Assay




FIG. 9

700 750 800 850 900 950 1000

Aprotinin Treated, Tryptase Standard Curves
(Serum v. Buffer)




FIG. 10

Tryptase Quantitation in Urine
(Aprotinin Treated v. Uninhibited Samples)




FIG. 11

**Enzymatic Inhibition of
recombinant human β -I tryptase**




FIG. 12

TOP SECRET//~~REF ID: A65660~~

**Enzymatic Inhibition of recombinant human β -II tryptase
by PRNK-CMK**




FIG. 13

**Enzymatic Inhibition of Factor Xa
by PRNK-CMK**




FIG. 14